Back to search

Ireland· IE-PA-PA0686/007/007

Optiray 350 mg I/ml PFS solution for injection

A ioversol product containing ioversol, registered in Ireland by Guerbet. The same ATC class is registered in 14 of our 19 countries.

ATC V08AB07

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedOptiray 350 mg I/ml PFS solution for …ATCV08AB07REGISTER NO.IE-PA-PA0686/007/007PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Ioversol is registered in 14 of 19 countries.

Countries holding a registration under ATC V08AB07 (ioversol), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 7 of them publish a price we can compare per daily dose

Ioversol · ATC V08AB07

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Ireland
  • Japan
  • Netherlands
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

HPRA (Ireland)
Active substance
Ioversol
Manufacturer
Guerbet
Country
Ireland (IE)
ATC code
V08AB07
ATC class
Ioversol
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    PA0686/007/007

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

188 interactions on record for ioversol.

Graded by severity as the source publishes them — 94 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Ioversol · interactions on record

188 records

  • 94 severe
  • 55 moderate
  • 39 info

Most severe, free to view

  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Amphotericin BA07AA07severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Ioversol in 13 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All ioversol products

Authorised across Europe · EMA

The same active substance is authorised in 21 EEA countries. Names it is sold under:

  • Austria · Optiray
  • Belgium · Optiject, Optiray
  • Czechia · Optiray
  • Germany · Optiray
  • Denmark · Optiray
  • Spain · Optiray, Optiray Ultraject
  • Finland · Optiray
  • France · Optiject, Optiray
  • United Kingdom (Northern Ireland) · Optiray
  • Greece · Optiray
  • Croatia · Optiray
  • Hungary · Optiray
  • Italy · Optiray
  • Luxembourg · Optiject, Optiray
  • Netherlands · Optiray
  • Norway · Optiray
  • Poland · Optiray
  • Portugal · Optiray
  • Romania · Optiray
  • Sweden · Optiray
  • Slovakia · Optiray

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/bcbe371d-3a6b-4127-af01-337c75fbbaca
GET /v1/drugs/bcbe371d-3a6b-4127-af01-337c75fbbaca?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "routes": [
    "Intravenous use"
  ],
  "source": "hpra",
  "atc_all": [
    "V08AB",
    "V08AB07"
  ],
  "strength": null,
  "pa_number": "PA0686/007/007",
  "substances": [
    "Ioversol"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Marketed",
  "authorised_at": "14/04/2000",
  "dispensing_status": "Product subject to Restricted Prescription (C)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about ioversol.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.